Restart Life Sciences Corp.
HEAL
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.75% | 39.33% | 84.62% | 357.58% | 44.43% |
| Depreciation & Amortization | -25.00% | -25.00% | -25.00% | -25.00% | -20.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.68% | 39.00% | 83.90% | 357.72% | 43.69% |
| Operating Income | -8.68% | -39.00% | -83.90% | -357.72% | -25.32% |
| Income Before Tax | -112,900.00% | -145.47% | -122.21% | -432.68% | 100.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -112,900.00% | -145.47% | -122.21% | -432.68% | 100.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -112,900.00% | -145.47% | -122.21% | -432.68% | 100.06% |
| EBIT | -8.68% | -39.00% | -83.90% | -357.72% | -25.32% |
| EBITDA | -8.75% | -39.33% | -84.62% | -359.13% | -25.54% |
| EPS Basic | -- | -118.94% | 2.22% | -195.83% | 100.00% |
| Normalized Basic EPS | 55.00% | 41.67% | 25.00% | -135.56% | -23.08% |
| EPS Diluted | -- | -133.18% | 1.37% | -187.84% | 100.00% |
| Normalized Diluted EPS | 50.00% | 38.24% | 25.00% | -135.56% | -10.77% |
| Average Basic Shares Outstanding | 135.62% | 141.96% | 126.86% | 80.52% | 13.29% |
| Average Diluted Shares Outstanding | 112.37% | 134.20% | 126.86% | 80.52% | 25.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |